- Min.Order :0 Metric Ton
- Purity: 99,9%
- Payment Terms : L/C,D/A,D/P,T/T,Other
Keywords
Femara verapamil verapamil
Quick Details
- Appearance:
- Application:
- PackAge:
- ProductionCapacity:|Metric Ton|Day
- Storage:
- Transportation:
Superiority:
Femara (generic name: letrozole; brand names include: Letrofil / Trozet / Femar) belongs to a group of medicines called aromatase inhibitors. They are also called "antiestrogens" because they act by reducing the production of estrogen in your body.
Femara is used to treat breast cancer in women who are post-menopausal - that is, women who no longer have periods, either naturally due to their age or after surgery or chemotherapy.
Femara is approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive early stage breast cancer. The benefits of Femara in clinical trials are based on 24 months of treatment.
Femara is also approved for the extended adjuvant treatment of early stage breast cancer in postmenopausal women who are within three months of completion of five years of tamoxifen therapy. The benefits of Femara in clinical trial are based on 24 months of treatment.
In addition, Femara is approved for the treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown breast cancer that has spread to another part of the body (metastatic cancer).Contact us for more details, more product and price list
Details:
Femara (generic name: letrozole; brand names include: Letrofil / Trozet / Femar) belongs to a group of medicines called aromatase inhibitors. They are also called "antiestrogens" because they act by reducing the production of estrogen in your body.
Femara is used to treat breast cancer in women who are post-menopausal - that is, women who no longer have periods, either naturally due to their age or after surgery or chemotherapy.
Femara is approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive early stage breast cancer. The benefits of Femara in clinical trials are based on 24 months of treatment.
Femara is also approved for the extended adjuvant treatment of early stage breast cancer in postmenopausal women who are within three months of completion of five years of tamoxifen therapy. The benefits of Femara in clinical trial are based on 24 months of treatment.
In addition, Femara is approved for the treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown breast cancer that has spread to another part of the body (metastatic cancer).Contact us for more details, more product and price list
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View